

3rd CRIG Industrial Partnering Event – Preliminary program

Online live stream and Communicatiehuis de Rode Bol (Ghent, BE) - Webpage

Friday 22 nd October, 2021	
8:00 - 8:55	Breakfast tables – Discussion tables of innovations on: a. Filling the gaps in oncology models: animal, PDX, spheroids, organoids, organ-on-a-chip, in silico (moderators: prof. O. De Wever and prof. G. Berx, UGent, CRIG) b. Unmet needs in cell and gene therapies (moderators: dr. D. De Groote and dr. T. Desmet, UGent, CRIG) c. Data science and data mining: the new life of old information (moderator: prof. L. Martens, VIB-UGent, CRIG)
9:00 - 9:10	Welcome - Prof. Olivier De Wever (CRIG chairman)
9:10 - 10:00	Plenary session - From an integrated drug discovery engine towards an innovative pipeline and personalized cancer care (dr. Greg Friberg, VP medical affairs EU, Latin-America, Middle-East, Africa and Canada - Amgen) - Room: AuditoRium
10:00 - 10:45	Parallel Sessions 1
	Session 1A - From R&D to the market: successful stories (moderator Dr. Dominic De Groote - UGent, CRIG) – Room: AuditoRium
	 Shining a light on dark matter: Development of long non-coding RNA targeted therapies in cancer – duo pitch #UGent spin-off Prof. Pieter Mestdagh (UGent, CRIG) Dr. Floor Stam (COO, Flamingo Therapeutics) T-BET and EOMES accelerate and enhance functional differentiation of human natural killer cells – duo pitch Laura Kiekens (UGent, CRIG) Dr. Jan Spanholtz (CSO, Glycostem) Trince, next generation transfection platform #UGent spin-off
	Dr. Philip Mathuis (CEO, TRINCE)
	Session 1B - Enabling models, clinical expertise & pediatric cancer (moderator Dr. Pieter Rondou - UGent, CRIG) – Room: CoeR+JaRdin • Advancing liquid biopsies for monitoring treatment efficacy in children with neuroblastoma Prof. Jo Vandesompele (UGent, CRIG) • Replicative stress drugging: a new paradigm for pediatric solid tumors Prof. Frank Speleman (UGent, CRIG)
	 The Cancer Center at Ghent University Hospital
10:45 - 11:10	Coffee break and sponsors showcase
11:10 - 12:00	Plenary session – Results from CARTITUDE-1: Phase 1b/2 study of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell maturation antigen—directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma (Yunsi Olyslager, Director Clinical Project Scientist Oncology, & Bie Van De Vloet, Senior Director Business Development - Janssen Pharmaceutical)

12:00 - 12:45 | Parallel Sessions 2

<u>Session 2A - Start-ups and spin-offs in the pipeline (moderator Dr. An Van Den Bulcke - UGent, CRIG)</u> Room: AuditoRium

- Gelgraft Medical –The solution towards minimally invasive breast reconstruction
 - Dr. Lana Van Damme (UGent, CRIG)
- BIO INX[©]: Your support in bioprinting
 - Dr. Jasper Van Hoorick (UGent, CRIG)
- Amalus: developing an exciting way of remodeling the TME
 - Dr. Bart Roman (UGent, CRIG)
- RadionD Improved breast cancer treatment by lowering radiation risk

#UGent spin-off

- Dr. Dina De Haeck (CEO, RadionD)
- SparXells™: igniting immunity against lung cancer and beyond
 - Prof. Dr. Karim Vermaelen (U(Z)Gent, CRIG)

<u>Session 2B – Bringing drug delivery to the market (moderator Prof. Katrien Remaut - UGent, CRIG)</u> Room: CoeR+JaRdin

- Biogelator Self-assembly hydrogel scaffolds for targeted drug delivery Prof. Annemieke Madder (UGent, CRIG)
- Repurposing of cationic amphiphiles to promote cytosolic delivery of RNA therapeutics / ERC grant RESPIRNA
 - Prof. Koen Raemdonck (UGent, CRIG)
- Nucleic acid therapeutics to enable a healthier tomorrow, TODAY
 - Dr. Dominik Witzigmann (CEO & co-founder, NanoVation Therapeutics)
- Computational modelling as in silico tool for drug delivery and planning of patientspecific treatments
 - Prof. Charlotte Debbaut (UGent, CRIG)
- Lipid nanoparticle platform technology for nucleic acid-based immunotherapy Prof. Bruno De Geest (UGent, CRIG)
- 12:45 13:30 | Speed dating
- 13:30 14:15 | Lunch, partnering and sponsors showcase
- 14:15 15:10 Plenary session Delivering access and autonomy through innovation (Dr. José Castillo, CEO Quantoom Biosciences) Room: AuditoRium
- 15:10 15:55 | Parallel Sessions 3

<u>Session 3A - Meet our experts (moderator Prof. Oliver De Wever - UGent, CRIG) - Room:</u> AuditoRium

- ERC grant NANOBUBBLE Laser-induced vapour nanobubbles for intracellular delivery of nanomaterials
 - Prof. Kevin Braeckmans (UGent, CRIG)
- ERC HUMYCO: towards defining the impact of mycotoxins on human cancer risk
 Prof. Marthe De Boevre (UGent, CRIG)
- PROTAC technology
 - Prof. Serge Van Calenbergh (UGent, CRIG)
- The novel ionbot proteomics search engine as a game-changer in cancer research Prof. Lennart Martens (VIB-UGent, CRIG)
- ZENTACC Targeting ZEB transcription factors for aggressive colorectal cancer therapy Prof. Geert Berx (UGent, CRIG)

<u>Session 3B - Digital and precision (immune) oncology (moderator Prof. Dr. Lieve Brochez – U(Z)Gent, CRIG) - Room: CoeR+JaRdin</u>

• The Data Science Institute UZ Gent

Prof. Dr. Kirsten Colpaert (UZGent)

- A flow cytometry-based computational pipeline to aid prognostication of AML patients
 Sarah Bonte (UGent, CRIG)
- myNEO: Using digital tumour fingerprints to personalise cancer vaccines

Dr. Bert Coessens (COO, myNeo)

Challenges in obtaining compliance, from R&D to GMP

Dr. Dominiek Rossillion (Business Development Manager, Quality by Design)

 Cytomine, a Digital Pathology platform dedicated to teaching, research and diagnosis, including Artificial Intelligence

Dr. Grégoire Vincke (Co-founder and CMBDO, Cytomine)

15:55 - 16:15 | Coffee break and sponsors showcase

16:15 - 17:00 | Parallel Sessions 4

<u>Session 4A - Immuno-oncology (moderator: Prof. Dr. Tessa Kerre – U(Z)Gent, CRIG) – Room:</u>
<u>AuditoRium</u>

- Immunotherapy clinical trials at Ghent University Hospital The DRUG unit Prof. Dr. Sylvie Rottey (U(Z)Gent, DRUG unit, CRIG)
- A-Kine™ platform: reprogramming cell targets for immune-oncology

Dr. Lennart Zabeau (Sr Research Scientist, Orionis Biosciences)

Production of advanced cell/gene therapeutics for clinical trials

Prof. Bart Vandekerckhove (UGent, CRIG)

• Introducing the UK's Cell and Gene Therapy Catapult, an independent centre of excellence to advance the growth of ATMP's

Dr. David Sexton (Business Developer, Cell and Gene Therapy Catapult)

Ten years of cancer immunotherapy with checkpoint inhibitors

Tom Van Lee (Disease Area Head Oncology, Bristol Myers Squibb)

<u>Session 4B - Early/non-invasive diagnostics and precision oncology (moderator Dr. Daisy Flamez – UGent, CRIG) - Room: CoeR+JaRdin</u>

 An extracellular vesicle-based toolbox to develop biomarkers for cancer detection and monitoring

Prof. An Hendrix (UGent, CRIG)

• Powerful insights with single-cell multi-omics: Co-detecting both genotype and phenotype from the same cell

Dr. Alocha Van den Houte (European Field Application Scientist, Mission Bio)

- Liquid biopsy by cfRRBS: making circulating free DNA methylome profiling routine Prof. Nico Callewaert (VIB-UGent, CRIG)
- The ProBio trial Molecular biomarkers for advancing personalised treatment decision in patients with metastatic prostate cancer

Dr. Bram de Laere (UGent, CRIG; Karolinska Institute)

 Mass spectrometry histochemistry: A direct route to oncologically relevant molecular biomarker discovery from histopathologically documented FFPE material

Prof. Peter Verhaert (Founder, ProteoFormiX)

17:00-17:10 Closing remarks - CRIG business unit

17:10 - 18:00 Networking reception & partnering discussions

Thanks to our sponsors

Platinum sponsors





Gold sponsor





Silver sponsors

















Bronze sponsors





